Microsatellite instability and manifestations of angiogenesis in stage IV of sporadic colorectal carcinoma.
Adult
Aged
Aged, 80 and over
Colorectal Neoplasms
/ pathology
Endothelial Progenitor Cells
/ metabolism
Female
Genomic Instability
/ genetics
Healthy Volunteers
/ statistics & numerical data
Humans
Liver Neoplasms
/ blood supply
Male
Microsatellite Instability
Middle Aged
Neoplasm Metastasis
/ pathology
Neoplasm Staging
Neovascularization, Pathologic
/ genetics
Telemedicine
/ methods
Vascular Endothelial Growth Factor A
/ blood
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
entrez:
5
1
2019
pubmed:
5
1
2019
medline:
17
1
2019
Statut:
ppublish
Résumé
Angiogenesis represents one of the critical mechanisms that facilitates carcinoma development. The study objective was to evaluate whether the microsatellite instability of colorectal carcinoma has impact on the angiogenesis activity in liver metastases.In a cohort of 80 randomly selected patients with stage IV colorectal carcinoma, 30% were recognized as microsatellite unstable (Microsatellite instability high-frequency (MSI-H)). The endothelial progenitor cell fraction (CD309+) was counted within the subpopulation of CD34+CD45+ cell and CD34+CD45- cells by flow cytometer. vascular endothelial growth factor (VEGF) factor levels were quantified in serum samples by enzyme-linked immunosorbent assay (ELISA). A control group consisted of 36 healthy volunteers. The relationship of genomic instability to angiogenesis activity was evaluated by multivariate analysis in comparison to the controls, adopting a P < .05 value as statistically significant.The expression of endothelial progenitor cells (EPCs) and VEGF was significantly higher in MSI-H compared to both microsatellite stability (MSS) patients and healthy controls (P < .008). Multi-parametric analysis showed microsatellite instability (OR=9.12, P < .01), metastases in both lobes (OR = 32.83, P < .001) and simultaneous metastases outside liver (OR = 8.32, P < .01), as independent factors associated with increased angiogenesis as assessed by measures of EPC and VEGF. A higher percentage of EPCs within the white blood cell fraction (total % EPCs / white blood cells (WBC)) and higher serum concentrations of VEGF were present in patients with MSI-H colorectal cancer, and not with MSS cancers (P < .001).MSI-H patients with colorectal cancer metastases are associated with the overexpression of circulating EPCs and VEGF, potentially driving angiogenesis. This should be considered in therapeutic decision-making.
Identifiants
pubmed: 30608431
doi: 10.1097/MD.0000000000013956
pii: 00005792-201901040-00051
pmc: PMC6344194
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Types de publication
Comparative Study
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13956Références
Future Oncol. 2011 Nov;7(11):1299-323
pubmed: 22044204
Gut. 2006 Jun;55(6):848-55
pubmed: 16299036
Int J Colorectal Dis. 2015 Mar;30(3):315-21
pubmed: 25598043
J Pathol. 2013 Feb;229(3):441-8
pubmed: 23165447
Ann Oncol. 2014 May;25(5):1032-8
pubmed: 24585723
BMC Cancer. 2010 May 14;10:203
pubmed: 20465852
Curr Treat Options Oncol. 2015 Jul;16(7):30
pubmed: 26031544
World J Gastroenterol. 2014 Jun 14;20(22):6809-14
pubmed: 24944470
Br Med Bull. 2004 Oct 27;70:87-104
pubmed: 15509717
Neoplasia. 2006 Feb;8(2):79-88
pubmed: 16611400
Nat Rev Cancer. 2008 Aug;8(8):579-91
pubmed: 18596824
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Virchows Arch. 2003 Feb;442(2):111-7
pubmed: 12596060
Anticancer Res. 2007 Jul-Aug;27(4C):2715-9
pubmed: 17695437
J Clin Oncol. 2013 Oct 10;31(29):3664-72
pubmed: 24019539
Br J Surg. 2000 Sep;87(9):1197-202
pubmed: 10971428
Int J Colorectal Dis. 2008 Nov;23(11):1033-9
pubmed: 18594845
Dig Surg. 2013;30(1):12-25
pubmed: 23595116
J Clin Oncol. 2011 Aug 10;29(23):3153-62
pubmed: 21747089
Br J Cancer. 2015 Jul 28;113(3):500-9
pubmed: 26068398
Cancer Res. 1995 Sep 15;55(18):3964-8
pubmed: 7664263
Curr Opin Oncol. 2009 Jul;21(4):369-73
pubmed: 19444104
J Clin Oncol. 2005 Mar 20;23(9):2038-48
pubmed: 15774795
Therap Adv Gastroenterol. 2013 Sep;6(5):381-95
pubmed: 24003339
J Clin Oncol. 2006 May 20;24(15):2359-67
pubmed: 16710035
BMC Cancer. 2015 Mar 21;15:156
pubmed: 25884995
Ann Oncol. 2010 Dec;21(12):2447-2448
pubmed: 21030382
Br J Cancer. 1998 Mar;77(6):998-1002
pubmed: 9528847
Gene Ther. 2002 May;9(10):631-41
pubmed: 12032709
Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9
pubmed: 25190710
Nat Med. 2001 Nov;7(11):1194-201
pubmed: 11689883
Gut. 2015 Jul;64(7):1132-47
pubmed: 24939570
Am J Clin Oncol. 2006 Aug;29(4):408-17
pubmed: 16891872
Ann Oncol. 2010 Dec;21(12):2382-2389
pubmed: 20497963
Oncol Rep. 2012 Oct;28(4):1217-24
pubmed: 22858892
Surgery. 2006 Mar;139(3):305-11
pubmed: 16546493
J Clin Invest. 1995 Apr;95(4):1789-97
pubmed: 7535799
Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2461-8
pubmed: 21930958
Ann Oncol. 2004 Jan;15(1):139-45
pubmed: 14679134
N Engl J Med. 2003 Jul 17;349(3):247-57
pubmed: 12867608
Mol Clin Oncol. 2016 Jun;4(6):909-917
pubmed: 27284422
J Clin Med. 2016 Jan 27;5(2):
pubmed: 26828526
Int J Mol Sci. 2013 Sep 03;14(9):18056-77
pubmed: 24005867
Biochim Biophys Acta. 2006 Aug;1766(1):159-66
pubmed: 16857321
Tissue Eng. 2006 Feb;12(2):331-5
pubmed: 16548691
J Clin Oncol. 2010 Jul 10;28(20):3210-2
pubmed: 20498404
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
World J Gastroenterol. 2013 Nov 28;19(44):7955-71
pubmed: 24307789
Cancer. 2011 Sep 1;117(17):4026-32
pubmed: 21858803
Atherosclerosis. 2008 Apr;197(2):496-503
pubmed: 18249408
Clin Cancer Res. 2009 Jan 1;15(1):267-73
pubmed: 19118054
World J Gastroenterol. 2012 Sep 21;18(35):4925-33
pubmed: 23002366
Therap Adv Gastroenterol. 2016 Nov;9(6):861-886
pubmed: 27803741
Nat Rev Cancer. 2002 Nov;2(11):826-35
pubmed: 12415253